09Dec 2022
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

Obesity is a growing global concern compounded by the limited availability of effective treatment options. The SURMOUNT development program aims to evaluate the efficacy and safety of tirzepatide as an adjunct to lifestyle intervention compared with a placebo on chronic weight management in adults with BMI ≥ 27 kg/m2 with or without type 2 diabetes. Across trials, participants have a mean age of 44.9 to 54.2 years, are primarily female (50.7% to 69.7%), and have a mean BMI of 36.1 to 38.9. The extensive assessment of once‐weekly tirzepatide in the global SURMOUNT program will detail the clinical effects of this first‐in‐class glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist in chronic weight management.

  • #endo-diabetology

Like

Save

Share